Le Lézard
Classified in: Health
Subjects: PDT, PER

APEX Orthopedics Investments Launches to Revolutionize Foot and Ankle Orthopedic Industry


AURORA, Colo., May 7, 2024 /PRNewswire/ -- APEX Orthopedics Investments, a groundbreaking asset management company dedicated to fostering innovation in the foot and ankle orthopedic sector, announces its establishment. Led by a team of experts and located in the University of Colorado's Anschutz Medical Campus, APEX Orthopedics Investments is poised to transform orthopedic device development.

Founded by CEO and President Christopher Banas, along with Chairman of the Board Murray Penner, MD, FRCSC; Chief Medical Officer Greg Berlet, MD, FRCSC, FAOA, FAAOS; and Chief Innovation Officer Stephen Brigido, DPM, FACFAS, APEX Orthopedics Investments is headquartered in Aurora, Colorado. This group brings over four decades of collective experience in successful product development, having launched 200+ products, generating a cumulative revenue of USD 3 billion.

Focused on investing in and incubating Class II and Class III device innovations, APEX Orthopedics Investments is committed to driving novel solutions in fixation hardware, midfoot arthrodesis, midfoot arthroplasty, and Achilles tendon. The company currently boasts 12 pending patents in the United States and internationally, along with 73 invention disclosures.

"Our mission at APEX Orthopedics Investments is to catalyze innovation within the foot and ankle orthopedic industry," stated Chris Banas, CEO and President of APEX Orthopedics Investments. "Through strategic investments and incubation, we aim to revolutionize patient care and outcomes while empowering orthopedic professionals with cutting-edge solutions."

APEX Orthopedics Investments has organized its intellectual property into four distinct portfolio companies, each focused on addressing critical needs within the field. These portfolio companies are poised to drive significant advancements and improvements in orthopedic care.

To learn more about APEX Orthopedics Investments and its transformative work, please visit www.APEXortho.net.

For media inquiries, please contact:

Christopher E. Banas
CEO & President
APEX Orthopedics Investments, LLC
Phone: (970) 333-9758
Email: [email protected]

About APEX Orthopedics Investments:

APEX Orthopedics Investments is an asset management company dedicated to developing Class II and III device innovations within the foot and ankle orthopedic industry. With a focus on driving advancements in fixation hardware, midfoot arthrodesis, midfoot arthroplasty, and Achilles tendon solutions, APEX Orthopedics Investments aims to revolutionize patient care and outcomes while empowering orthopedic professionals with cutting-edge solutions. Based in Aurora, Colorado, the company brings together a team of experts with over four decades of collective experience in product development, having launched 200+ products, yielding a combined revenue of USD 3 billion.

SOURCE Apex Orthopedics Investments, LLC


These press releases may also interest you

18 mai 2024
Celltrion partners with TV star Mollie Pearce to launch the second installation of the Where's Crohn's & Colitis (CC)? campaign for this year's World IBD Day (19 May 2024). The campaign focuses on access to IBD care and treatment as the burden of...

18 mai 2024
On Wednesday, May 15, Red Door Community hosted their annual Celebrating Women Working and Living with Cancer Luncheon at the Metropolitan Club in New York City. The event raised more than $300,000 while shining a light on the women who inspire us...

18 mai 2024
Product: Kalihim (Philippine Bread Roll) Issue: Food - Allergen - Egg Distribution: British Columbia See the affected products and product photos for this recall SOURCE Canadian Food Inspection Agency (CFIA)

18 mai 2024
The global industrial automation market in life sciences industry  size is estimated to grow by USD 5.06 bn from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of  11.4%  during the forecast period. ...

18 mai 2024
Boston Scientific Corporation today announced positive six-month results from the ongoing pivotal MODULAR ATP clinical trial of the mCRMtm System,* the first modular cardiac rhythm management (CRM) system that consists of the EMBLEMtm Subcutaneous...

18 mai 2024
Gilead Sciences, Inc. , following the recent acquisition of CymaBay Therapeutics, Inc., today announced interim results from the ongoing ASSURE study demonstrating treatment with seladelpar, an investigational PPAR delta agonist, led to improvements...



News published on and distributed by: